# **SAFETY DATA SHEETS**

# This SDS packet was issued with item:

078946845

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078946848 078946849 078946851 078946853 078946856 078946857 078946858

Product Name: Rederox™ (deracoxib) Chewable Tablets Issue Date: 10/2021

Version No: 2021-1



SECTION 1: IDENTIFICATION	
1.1 Product identifier	
Product name	Rederox™ (deracoxib) Chewable Tablets 12 mg, 25 mg, 75 mg and 100 mg
Synonyms	Not available
Proper shipping name	Not available
Other means of identification	None
1.2 Relevant identified uses of the	ne substances or mixture and uses advised against
Recommended uses	For the control of pain and inflammation associated with osteoarthritis in dogs, for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs and for the control of postoperative pain and inflammation associated with dental surgery in dogs.
	For professional use only.
	Federal law restricts this drug to be used by or on the order of a licensed veterinarian.
Uses advised against	Not for human use, do not use in cats
1.3 Details of the supplier of the substance or mixture	
Registered company name	Dechra Veterinary Products
Address	7015 College Blvd, Suite 525 Overland Park KS 66211 USA
Telephone	866-933-2472
Fax	Not available
Email	Not available
1.4 Emergency telephone numbers	
Dechra (US)	866-933-2472

Product Name: Rederox™ (deracoxib) Chewable Tablets

Issue Date: 10/2021 Version No: 2021-1



### **SECTION 2: HAZARDS IDENTIFICATION**

### 2.1 Classification of the substance or mixture

# **Classification (GHS-US)**

This product is a drug, as defined by the US Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.). It is in solid, final form for direct administration to the patient. Therefore, it is exempt from the US 2012 Hazard Communication Standard, as defined in the 29 CFR 1910.1200(b)(6)(vii).

### 2.2 Label elements

No labeling applicable

### 2.3 Other Hazards

No additional information available

# 2.4 Unknown Acute Toxicity (GHS-US)

No data available

SECTION 3: COMPOSITION/INFORMATION ON THE INGREDIENTS				
3.1 Substances				
See section below f	or composition of Mixtures.			
3.2 Mixtures				
CAS No	Approximate quantity	Name		
169590-41-4	12/25/75/100 mg	<u>deracoxib</u>		
not available	q.s.	non-hazardous ingredients		

# **SECTION 4: FIRST AID MEASURES**

# 4.1 Description of first aid measures

### General advice:

If you feel unwell, seek medical advice.

### **Eye contact:**

Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician if irritation persist.

#### Skin contact:

Wash off with soap and plenty of water. Consult a physician if irritation persist.

#### Inhalation:

The risk of inhalation exposure is negligible when product is in its final packaged form. If exposed and become symptomatic, move to fresh air and get medical attention if symptoms persist.

### Ingestion:

Rinse mouth with water. Consult a physician.

### 4.2 Most important symptoms and effects, both acute and delayed

### Inhalation:

Due to the product's final form, inhalation is an unlikely route of exposure.

Product Name: Rederox™ (deracoxib) Chewable Tablets

Issue Date: 10/2021 Version No: 2021-1



Skin contact:

None expected under normal conditions of use,

Eye contact:

None expected under normal conditions of use.

Ingestion:

Ingestion of the product is likely to be harmful or have adverse effects.

**Chronic symptoms:** 

None expected under normal conditions of use.

4.3 Indication of any immediate medical attention and special treatment needed:

Treat symptomatically.

### **SECTION 5: FIRE FIGHTING MEASURES**

# 5.1 Extinguishing media

**Suitable extinguishing media:** Use extinguishing media appropriate for surrounding fire. **Unsuitable extinguishing media:** None known.

# 5.2 Special hazards arising from the substance or mixture

Fire hazard: Not considered flammable.

**Explosion hazard:** Product itself is not explosive.

Reactivity: Hazardous reactions will not occur under normal conditions.

**Special fire fighting procedure:** Fire may cause release of carbon monoxide, carbon dioxide. In the event of fire, wear self-contained breathing apparatus. Prevent fire. Prevent water from contaminating surface water or the ground water system.

### 5.3 Advice for fire-fighters:

**Precautionary measures fire:** Exercise caution when fighting any chemical fire. **Firefighting instructions:** Use water spray or fog for cooling exposed containers.

Protection during firefighting: Do not enter fire area without proper protective equipment,

including respiratory protection.

### **SECTION 6: ACCIDENTAL RELEASE MEASURES**

## 6.1 Personal precautions, protective equipment and emergency procedures

**General measures**: Avoid unnecessary contact with skin, eyes and clothing.

# 6.1.1. For non-emergency personnel

Protective equipment: Use appropriate personal protection equipment (PPE).

Emergency procedures: Evacuate unnecessary personnel.

## 6.1.2. For emergency responders

**Protective equipment:** Equip cleanup crew with proper protection.

**Emergency procedures:** Upon arrival at the scene, a first responder is expected to recognize the presence of dangerous goods, protect oneself and the public, secure the area, and call for the assistance of trained personnel as soon as conditions permit.

### 6.2 Environmental precautions

Avoid release to environment.

### 6.3 Methods and material for containment and cleaning up

Product Name: Rederox™ (deracoxib) Chewable Tablets Issue Date: 10/2021

Version No: 2021-1



For containment	Contain and collect as any solid.	
Methods for cleaning up	Dispose of waste in accordance with local, state and federal regulations.	
6.4 References to other sections		
See Heading 8. Exposure controls and personal protection. For further information refer to section 13.		

SECTION 7: HANDLING AND STORAGE			
7.1 Precautions for safe handling			
Hygiene measures	Avoid dust formation. Avoid contact with skin, eyes and clothing. Take		
	measures to prevent the buildup of electrostatic charge. Keep away		
	from open flames, hot surfaces and sources of ignition. Use		
	appropriate personal protective equipment when handling and		
	observe good personal hygiene measures after handling.		
7.2 Conditions for safe storage, including any incompatibilities			
Technical measures	Comply with applicable regulations.		
Storage conditions	Store at 20° to 25°C (68° to 77°F), excursions permitted between		
	15° and 30°C (between 59° and 86°F). [See USP controlled room		
	temperature]. Store tablets in a tight container only.		
7.3 Specific end use(s)			
Non-steroidal anti-inflammatory drug. For professional use only. Federal (U.S.A.) law			
restricts this drug to be used by or on the order of a licensed veterinarian.			

SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION		
0.4. 0 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1		
8.1 Control parameters		
For substances listed in se	ction 3 that are not listed here, there are no established exposure	
limits from the manufacturer, supplier, importer, or the appropriate advisory agency including:		
ACGIH (TLV), NIOSH (REL), or OSHA (PEL).		
8.2 Exposure controls		
Appropriate engineering	None required under normal operating condition.	
controls		
Personal protective	Not generally required. The use of personal protective	
equipment	equipment may be necessary as conditions warrant.	
Hand protection	None required under normal operating condition.	
Eye protection	None required under normal operating condition.	
Skin and body protection	Wear suitable protective clothing if skin contact with drug product	
	is possible.	
Respiratory protection	No protection equipment is needed under normal use conditions.	
	If exposure limits are exceeded or irritation is experienced,	
	ventilation and excavation may be required.	

Product Name: Rederox™ (deracoxib) Chewable Tablets

Issue Date: 10/2021 Version No: 2021-1



### **SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**

### 9.1 Information on basic physical and chemical properties

**Appearance:** Light brown colored tablet.

Physical state: Solid Odor: Not Available

Odor threshold: Not Available pH (as supplied): Not Available

Melting point / freezing point (degrees C):

Not Available

Initial boiling point and boiling range: Not

Available

Flash point: Not Applicable Evaporation rate: Not Available Flammability: Not Available

Upper / lower flammability or explosive

limits: Not Available

Vapor pressure: Not Available

Relative density (at degrees C): Not

Available

Solubility in water and solvents (mg/l): Not

Available

Vapor density: Not Available

Auto ignition temperature (degrees C):

Not Applicable

**Decomposition temperature (degrees C):** 

Not Available

Viscosity (degrees C): Not Available

Explosive properties: None Oxidizing properties: None

Partition coefficient: Not Available Molecular weight: Not Applicable

Taste: Not Available

**Surface tension:** Not Available **Volatile component:** Not Available

Gas group: Not Available pH as a solution: Not Available

VOC g/L: Not Available

Specific gravity @ 20 degrees C (water =

1): Not Available

### 9.2 Other information

No additional information available

10: REACTIVITY AND STABILITY	
10.1 Reactivity	Hazardous reactions will not occur under normal conditions.
10.2 Chemical stability	Stable under recommended handling and storage conditions.
10.3 Possibility of hazardous reactions	None under normal condition.
10.4 Conditions to avoid	None.
10.5 Hazardous decomposition products	Decomposition will not occur under normal conditions

SECTION 11: TOXICOLOGICAL INFORMATION		
Acute toxicity	Oral LD <sub>50</sub> (rat) >600 mg/kg	
Local effects	Not classified	
Reproductive effects	Not classified	
Mutagenicity	Not classified	

Product Name: Rederox™ (deracoxib) Chewable Tablets

Issue Date: 10/2021 Version No: 2021-1



### **SECTION 12: ECOLOGICAL INFORMATION**

- 12.1 Toxicity: No additional information available
- 12.2 Persistence and degradability: No additional information available
- 12.3 Bioaccumulative potential: No additional information available
- **12.4 Mobility in soil:** No additional information available
- 12.5 Other adverse effects: No additional information available

### **SECTION 13: DISPOSAL CONSIDERATIONS**

### 13.1 Waste treatment methods

**Waste Disposal Recommendations:** Dispose of waste material in accordance with all local, regional, national, and international regulations.

### **SECTION 14: TRANSPORT INFORMATION**

Transport according to all local, state and federal regulation

### **SECTION 15: REGULATORY INFORMATION**

No additional information available

### SECTION 16: OTHER INFORMATION

Revision date: 20 October 2021

Revision number 1.0

The information provided in this Safety Data Sheet has been compiled by Dechra Veterinary Products LLC using a number of different sources, and is correct to the best of its knowledge, information and belief as of the date of its publication. However, Dechra Veterinary Products LLC makes no warranties, express or implied, in relation to the information set out in this SDS, including, without limitation, as to its accuracy/completeness. The information provided is not a quality specification, and is prepared by way of guidance as to the safe handling, use, processing, storage, transportation, disposal and release of the relevant products referred to. The user is responsible for determining whether or not the product is fit for any particular purpose and/or suitable for the user's proposed method of use and application.

Copyright, 2021 Dechra Veterinary Products LLC. All rights reserved.

Copying and/or downloading of this information for the purpose of properly utilizing Dechra Veterinary Products LLC products is permitted provided that: (1) the information is copied in full with no changes unless prior written agreement is obtained Dechra Veterinary Products LLC, and (2) neither the copy nor the original is resold or otherwise distributed for the purposes of making a profit thereon.